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Thesis Abstract
One of the major hallmarks of central nervous system injury is astrocyte
proliferation. However, not aU astrocytes enter the cell cycle following damage, and the
mechanism that determines which astrocytes will proliferate and which will remain
quiescent has not been elucidated. Protein tyrosine phosphorylation has been shown to
play an important role in the regulation of the cell cycle in a number of different systems,
and has been implicated in astrocyte proliferation and differentiation. The protein tyrosine
phosphatase SHP-1 modulates cellular proliferation in the hematopoietic system and is
involved in various growth factor signal transduction cascades. Our laboratory has
previously shown an increase in SHP-1 immunoreactivity in a subpopulation of astrocytes
following deafferentation of the chick auditory brainstem. These SHP-1-positive cells
appear to be those that do not enter the cell cycle following deafferentation. The present
study examined whether manipulation of cellular proliferation in vitro modifies the
expression of SHP-1 immunoreactivity and attempted to identify factors that may contribute
to the increase in SHP-1 expression following CNS injury.
Mixed neural/glial cultures were prepared from E14 chick brainstems (8-30
animals/run). SHP-1 immunoreactivity was examined when the cultures were growing,
growth arrested, and growing again after the réintroduction of serum into the cultures. In
actively proliferating cultures, SHP-1 immunoreactivity is localized to the cytoplasm of a
subset o f cells, while in growth arrested cultures, SHP-1 immunoreactivity appears to be
localized to the nucleus of some cells. Cultures which have been induced to divide again
following growth arrest contain numerous that once again exhibit a cytoplasmic distribution
o f SHP-1.
The protein tyrosine phosphatase (FTPase) inhibitor sodium orthovanadate was
then introduced into growing cultures and the rate of proliferation was examined after
PTPase activity was inhibited. Sodium orthovanadate was found to cause an increase in
proliferation but does not appear to dramatically alter either SHP-1 intensity or distribution
in these cultures.
Neuronal debris as well as various growth factors have been shown to be mitogenic
for glial cells and are thought to play a role in the glial response to injury. SHP-1 has been
shown to interact with several growth factors, including epidermal growth factor (EGF),
interleukin-3 (IL-3) and granulocyte macrophage-colony stimulating factor (GM-CSF). All
three growth factors are mitogenic in our culture system and also resulted in slightly
differing patterns of SHP-1 expression. Addition of EGF to growth arrested cultures
results in a nuclear distribution of SHP-1, while addition of GM-CSF or IL-3 produces
both a cytoplasmic and nuclear distribution of SHP-1 immunoreactivity.
Finally, the role of neuronal debris on SHP-1 expression was examined by
selectively killing neurons by excitotoxicity in confluent cultures. While SHP-1 positive
ceUs can be found next to healthy neurons, dead or dying neurons are found in areas
devoid o f SHP-1 positive cells. This is in contrast to the pattern observed for glial
fibrillary acidic protein (GFAP) positive astrocytes, which are often located directly under,
or adjacent to, dying neurons.
These results demonstrate that SHP-1 expression can be altered by modulating both
cellular proliferation and by manipulating the extracellular environment. Significantly,
inhibition of tyrosine phosphatase activity results in increased proliferation, indicating that
tyrosine phosphatases such as SHP-1 may play a key role in regulating the glial response to
injury.
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IN T R O D U C T IO N
The astrocyte response to central nervous (CNS) injury has been
traditionally characterized in terms of morphological changes, including
proliferation, process extension, and increased levels of the glial
intermediate fibrillary acidic protein (GFAP; Reier and Houle 1988; Reier et
al. 1983; Graeber and Kreutzberg 1986; Graeber and Kreutzberg 1988;
Tetzlaff et al. 1988; Condorelli et al. 1990; Steward et al. 1990). Astrocytic
proliferation following injury results in an astroglial scar and these events
are referred to as “reactive gliosis” (Reier and Houle 1988). While it is
generally believed that the formation of the neuro/glial scar is an
impediment to axonal regeneration (Reier and Houle 1988), many reactive
astrocytes appear to engage in activities that appear to promote rather
than

inhibit neuronal regeneration.

Such

activities

include

the

phagocytosis of neuronal debris, reconstruction of a functional neural
tissue, reconstitution of glial limitans, synthesis of extracellular matrix
proteins, and the synthesis of numerous neurotrophic factors (which are
thought to enhance neuronal survival and induce neuronal growth and
differentiation; Reier and Houle 1988; Vaca and Wendt 1992; CarmenKrzan et al. 1991; Banker 1980; McCafferty 1984). While the end result is
well characterized, neither the signals that regulate astrocyte proliferation
following injury, nor the basis on which certain subsets of astrocytes enter
the cell cycle are well understood. The process, however, must be well
controlled to allow for the formation of a limited glial scar, as massive
astrocyte proliferation leading to large glial masses (i.e. tumors) at the site
of injury does not occur.

It is clear that reactive astrocytes have
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developed control mechanisms that limit both the window of time in which
astrocytes proliferate following CNS damage, as well as the number of cells
that actually progress through the cell cycle. The role that proliferating vs.
non-proliferating astrocytes play following CNS damage remains to be
elucidated and it may be that those signals that send certain populations of
astrocytes into the cell cycle also influence the degree of functional
recovery that can occur after damage.
Previous studies in our laboratory have found a subset of astrocytes
in the chick auditory brainstem that upregulate the expression of the
protein tyrosine phosphatase SHP-1 following CNS injury. It may be that
this enzyme plays a role in regulating which astrocytes enter the cell cycle
following damage.

Cell Cycle Regulation

The phases of the cell cycle are classified as follows: mitosis (M),
first gap (Gl), DNA synthesis (S) and second gap (02). There is also a
resting stage (Go) of variable duration from early Gl.

The phases are

defined by cytologic criteria and different protein complexes are activated
in order to trigger progression through the cell cycle (Grana and Reddy
1995). The advance through checkpoints (in particular Gl-S and G2-M) is
regulated by protein complexes composed of a regulatory protein (cyclin)
and a catalytic protein (cyclin-dependent kinase; CDK) (Cavalla and
Schiffer 1997; Schiffer et al. 1997). These protein complexes form the core

regulatory machinery for the cell cycle and loss of these regulatory
mechanisms will result in uncontrolled proliferation.

Protein Tyrosine Phosphorylation

The phosphorylation state of proteins and enzymes is critical for
many cellular functions including cell division. The phosphorylation of
tyrosine residues has been shown to regulate both cellular proliferation as
well as differentiation (Bishop 1991: Cantley et al. 1991; Hunter 1991).
This phosphorylation is regulated by both protein tyrosine kinases (PTKs),
which phosphorylate tyrosine residues, and protein tyrosine phosphatases
(PTPs), which dephosphorylate tyrosine residues. However, it is clear that
the balance between the activities of PTKs and PTPs is critical for both
cellular proliferation and differentiation.
Protein tyrosine phosphatases (PTPs) have been shown to both
decrease as well as indirectly increase tyrosine phosphorylation. The PTPs
are obviously able to dephosphorylate proteins, including kinases, which
in some circumstances leads to an increase in kinase activity with a
resulting increase in phosphorylation. While there is evidence that PTPs
can reverse the effect of PTKs, there is also increasing evidence that PTPs
are involved in a synergistic effect with PTKs (Walton and Dixon 1993;
Saito and Streuli, 1991; Fischer et al. 1991; Brautigan 1992).
Of particular

interest

is

the

fact

that

protein

tyrosine

phosphorylation has also been implicated in both astrocyte proliferation
and differentiation. The differentiation of 02A progenitor cells into type 2

astrocytes results in a decrease in several tyrosine phosphorylated proteins
(Ingraham and Maness 1990). In addition, the phorbol ester phorbol 12myristate-13-acetate (PMA), which has been shown to induce synthesis of
the protein tyrosine phosphatase SHP-1 (Zhao et al. 1994), also induces
changes in astrocyte morphology (Harrison and Mobley 1991). Growth
factors that activate protein tyrosine kinase receptors, including epidermal
growth factor, fibroblast growth factor, platelet-derived growth factor,
interleukin-1, and insulin-like growth factor, are mitogenic for astrocytes in
vitro (Huff and Schrier 1990; Malhotra et al. 1990; Langan et al. 1994).
Finally, modulation of tyrosine phosphorylation mediated by PTPs,
participates in both cell cycle regulation and differentiation.

Whether

these enzymes activate or inhibit cell division appears to be dependent
upon the individual phosphatase and the cellular environment in which it
is expressed (Lau and Bay link 1993; Neel 1993).

Protein Tyrosine Phosphatase SHP-1

SHP-1 (also known as PTPIC, SHPTP-1, SHP, and HCP) is a
cytoplasmic tyrosine phosphatase.

It contains 2 5rc-homolgy 2 (SH2)

domains, an uninterrupted PTP region, and a C-terminal extension that has
several potential phosphorylation sites. The SH2 domain is a conserved
region of about 100 amino acids and was originally identified in multiple
members of the src subfamily of non-transmembrane PTKs.

The SH2

domains fall within a non-catalytic region of the cytoplasmic protein
tyrosine kinases and are thought to be involved the regulation of the

kinase’s activity (Sadowski et al. 1986). The structure of the SH2 domain
has been identified in other cytoplasmic signaling proteins (Feng and
Pawson 1994) and it is this structure that promotes protein-protein
interaction by binding to specific phosphorylated tyrosine residues (Koch
et al. 1991; for review see Schlessinger and Ullrich 1992).

The SH2

domains of PTPs exert an inhibitory influence on the activity of these
enzymes when not engaged. When the SH2 domains are engaged by
protein substrates, the enzyme becomes activated (Neel 1993).

Recent

studies have also shown that recombinant SHP-1 lacking its SH2 domains
is enzymatically activated against phosphotyrosyl peptides (Pei et al. 1993;
Townley et al. 1993).
The C-terminal has also been shown to be important in the
activation of the phosphatase. The C-terminus of the phosphatase serves
as an auto-inhibitor of this enzyme. Limited trypsinolysis of SHP-1, which
results in the removal of the C-terminal 41 amino acids, leads to substantial
activation (Zhao et al. 1993a; 1993b). The C-terminal domain of SHP-1
may serve both to fold the enzyme into proper conformation to bind
protein substrates and also inhibit catalysis. Finally, it has been shown that
when SHP-1 is activated, it translocates to a hpid membrane (Zhao et al.
1994). The specific cellular membrane has yet to be identified.
SHP-1 has been most thoroughly characterized in hematopoietic
cells, where it is expressed strongly (Plutzky et al. 1992; Yi et al. 1993;
David et al. 1995; Krautwald et al. 1996). However, SHP-1 has also been
found in a variety of cells including: human epithelial carcinoma cells
(Tomic et al. 1995), human cervical carcinoma cells (You and Zhao 1997),

human embryonic kidney cells (Bouchard et al. 1994), rat liver cells (Ram
and Waxman 1997), rat pancreatic tumor cells (Cambillau et al. 1995) and
mouse astrocytes (Massa and Wu 1996).
In general, SHP-1 phosphatase activity is inversely related to
growth and proliferation of cells. Recently, several groups have studied
SHP-1 expression in different systems. The consensus has been that SHP-1
is playing a negative role in cellular growth and proliferation. For example
somatostatin inhibits cellular proliferation and stimulates SHP-1 activity in
Chinese hamster ovary cells (Lopez et al. 1996; 1997). The glucocorticoid
dexamethasone inhibits proliferation of rat pancreatic tumor acinar cells
and selectively increases SHP-1 expression and activation several-fold
(Cambillau et al. 1995).

Phorbol esters inhibit proliferative activity in

human leukemia cells and stimulate expression and activity of SHP-1
(Uchida et al. 1993: Zhao et al. 1994).
interleukin-3-induced growth

In a related observation, the

stimulation of hematopoietic cells is

suppressed by the induction of SHP-1 expression (Yi et al. 1993).
However, a negative role for SHP-1 in cellular proliferation is not universal.
Overexpression of SHP-1 in epidermal growth-factor-activated human
embryonic kidney cells suggests a positive role for the phosphatase in
proliferative activity (Su et al. 1996). It has become clear that the role of
SHP-1 in growth, proliferation, and differentiation of cells is apparently
dependent on context: including cell type, signaling molecules, and
perhaps other factors.
The signal transduction pathway of SHP-1 has yet to be fully
elucidated. However, SHP-1 has been shown to play a role in growth

factor mediated signal transduction in a variety of different cells.

For

example, SHP-1 binds to the interleukin 3 (IL-3) receptor following ligand
binding and can dephosphorylate the B chain of the receptor in vitro (Yi
and Ihle 1993). SHP-1 also associates with activated EGF receptors (You
and Zhao 1997; Tenev et al. 1997) and may also dephosphorylate novel
substrates critical for GM-CSF signaling in mouse macrophages (Yang et
However, the in vivo target substrates and resulting signal

al. 1998).

transduction cascades activated by SHP-1 have not been determined for
most cells, and probably differ among various cell types.
As mentioned above, the role of SHP-1 in vivo remains to be
elucidated. The best characterized in vivo model is a mouse knockout for
SHP-1; ihQ Motheaten (me) mouse, named after the motheaten appearance
of their coats. Classically viewed as a severe combined immunodeficency
disease.

Motheaten mice do have profound abnormalities in immune

function and survive only a few weeks to a few months (Bignon and
Siminovitch 1994; Shultz and Sidman 1987).

There is also a profound

auto-immunity, marked by dramatic macrophage hyperproliferation.

SHP-1 Expression in Astrocytes of the Deafferented Auditory
Brainstem

Our laboratory has previously described a subset of astrocytes in
the chick auditory brainstem that express SHP-1 (Lurie et al. 1993). SHP-1
immunoreactivity increases strongly in response to deafferentation, and
this is correlated with increased astrocyte proliferation. However, SHP-1
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immunoreactivity appears to be upregulated in astrocytes that fail to enter
the cell cycle following injury (Lurie et al. 1997; Lurie et al. 1998). Thus,
SHP-1 may play a role in regulating the number of astrocytes that
proliferate in response to deafferentation, thereby limiting the size of the
glial scar. A related observation has been in the rat hippocampus, where
SHP-1 inununoreactivity in glial cells increases following either excitotoxic
or metabolic-induced injury (Willis et al. 1997).

Taken together, these

results clearly indicate that SHP-1 is an important component of the CNS
response to injury.
We hypothesize that once a signal for proliferation has been
initiated (such as deafferentation or other CNS injury) the affected glial
cells can take one of two different pathways. One pathway is to divide in
response to the signal, the other pathway is to actively prevent cell
division in the presence of a signal to divide. SHP-1 may be part of the
intracellular cascade that is turned on to prevent some glial cells from
proliferating in the presence of an extrinsic signal to divide. When there is
no such signal to divide, i.e. in the uninjured brain, there is no need to
upregulate SHP-1, and it is expression remains low. Only when there is an
extrinsic signal to divide does a regulatory mechanism become important,
and SHP-1 is upregulated. Obviously, some sort of regulatory mechanism
must be activated in order to modulate the glial response to injury. If every
astrocyte or microglia entered the cell cycle following damage, they would
overrun each other with potentially negative consequences.
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Specific Objectives of the Current Project
The overall goal of this project was to determine whether SHP-1
played a role in regulating glial proliferation in vitro.
asked three questions:

Specifically, we

1) Does manipulation of the cell cycle change

either the amount and/or distribution of SHP-1?, and 2) Does inhibition of
protein tyrosine phosphatase activity alter glial proliferation?, and 3) What
extracellular signals lead to changes in both SHP-1 expression and glial
proliferation? In order to address these questions, the following series of
experiments were performed using mixed neural/glial cultures from the
chick brainstem.

1. The cell cycle was manipulated in vitro in order to observe changes in
SHP-1 expression.
2. The tyrosine phosphatase inhibitor sodium orthovanadate was added to
cultures and changes in both SHP-1 expression and proliferation were
monitored.
3. The growth factors EGF, IL-3 and GM-CSF were added to cultures in
order to determine whether these factors played a role in upregulating
SHP-1 expression following injury in vivo.
4. Neurons in mixed cultures were killed using the excitotoxin NMDA in
order to determine whether neuronal death plays a role in upregulating
SHP-1 expression following injury in vivo.

M ATERIALS AND M ETHODS

Subjects
Embryonic chicks (white leghorn; Truslow Farms Chestertown,
MD) were used for this investigation. Fertilized eggs were incubated at
37-38% in a humidified environment in the University of Montana
AAALAC-approved animal care facilities. Brainstems were removed from
stage 41 (embryonic day E-14) animals using the Hamburger and
Hamilton’s (1951) staging scheme. Eight to thirty embryos were used for
each experiment.

All procedures were approved by the University of

Montana Institutional Animal Care and Use Committee.

In vitro preparation
Embryonic day-14 chicks were sacrificed by decapitation.

The

brainstems were dissected from the embryos and freed of the meninges
(performed in calcium/magnesium free buffer: CMF). The tissue was then
transferred to a 35 ml petri dish, minced with a sterile razor blade in Earle’s
Balanced Salt Solution (EBSS), and then placed in a vial containing 20
units papain/500 units DNase in 0.5 mM EDTA (Worthington Biochemical
Corp.) The vial containing the cells was placed in a 37% water bath for
20 minutes with sterile 95%

COj bubbled through the solution.

Cells were then gently triturated with a flame constricted glass pipette for
5 minutes. The suspension was next placed in a 15 ml centrifuge tube and
centrifuged at 300 x g for five minutes at room temperature. The
10
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supernatant was then discarded and 2.7 mis EBSS/333 units DNase and
1.665 units ovomucoid protease inhibitor was added to the cells. The
solution was next centrifuged at 70 x g for six minutes (Worthington
Biochemical Corp.; Papain Dissociation System).

The pellet was

resuspended in 4 mis of EMEM (minimum essential medium with EBSS;
GibcoBRL) containing 10% horse serum (HS; GibcoBRL), 10% fetal
bovine serum (PBS) (Hyclone), 1% penicillin-streptomycin (GibcoBRL), 2
mM L-glutamine and 1% Fungizone (GibcoBRL).

Cells were counted

using a hemacytometer (Fisher Scientific), and then plated in 12 well plates
with poly-L-lysine coated coverslips at a seeding density of 5 X 10^
cells/well. After plating, the cells were placed in an incubator at 37®C
under an atmosphere of 5% CO^ in air.

Culture Experiments
Manipulation o f the cell cycle
Once the cultures were placed in the incubators they were allowed
to grow for 6 days. At day 6, one third of the plates were pulsed for 6
hours with the thymidine analog, BrdU (Ipg/ml; Sigma), to label dividing
cells. After 6 hours, the cultures were fixed in ice-cold methanol for 2
minutes or 4% paraformaldehyde for 15 minutes, rinsed in 0.1 M Tris buffer,
pH 7.4 and then processed for BrdU, SHP-1, GFAP, 0X42, CNP and
Neurofilament immunohistochemistry.

The remaining plates were then

gradually serum depleted over the next 3 days in order to growth arrest
the cultures.

This was accomplished by gradually reducing

the

concentrations of fetal bovine serum and horse serum from 10% (days 1-6)
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to 5% (day 6) to 3% (day 1 \ and finally 1% (day 8). On the 9th day the
medium was changed to a Neuralbasal medium with B-27 supplement
(GibcoBRL).

This medium contains no serum or proliferative growth

factors but has been shown to sustain cells in vitro (Brewer et al., 1993;
1995) The cultures were then left in the Neuralbasal medium for 6 days
(with a media change at day 3). At day 15, half of the cultures were pulsed
with BrdU for 6 hours, fixed in ice-cold methanol and processed for the
antibodies stated above. Serum was added to the remaining cultures at
day 15 (EMEM 10% FBS/10% HS) and the cells were allowed to grow for
an additional 3 days. At day 18 the remaining plates were pulsed with
BrdU for 6 hours, fixed, and processed for immunocytochemistry.

Addition o f the phosphatase inhibitor Sodium Orthovanadate
Cultures were allowed to grow for 7 days in EMEM 10% FBS/10%
HS (at day 6 the media was changed). On day 7, sodium orthovanadate
was added to the cultures at concentrations of 10, 20, 30, 40 and 50 p,M.
Twenty-four hours after the addition of sodium orthovanadate, the
cultures were pulsed with BrdU for 6 hours. The cells were then fixed and
processed for BrdU and SHP-1 immunohistochemistry.

Addition o f growth factors
For some experiments, growth factors instead of serum were added
back to the cultures at day 15. These growth factors included EGF, IL-3
and GM-CSF (Becton Dickinson; see results for specific concentrations).
The cultures were then pulsed with BrdU at day 16 (24 hours after
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addition of growth factors or serum) and day 18 (72 hours after addition of
growth factors or serum). After each pulse the cells were fixed with either
ice-cold methanol or 4% paraformaldehyde for 15 minutes and then
processed for BrdU and SHP-1 immunohistochemistry.

Addition o f NMDA
Cultures were allowed to grow in EMEM 10% FBS/10% HS for 11
days. The media was changed on days 6, 9 and 11. N-methyl-D-aspartate
(NMDA; Tocris) was introduced on day 11 at concentrations of 25, 50, 75
and lOOjiM. Twenty-four and 48 hours after the addition of NMDA, the
cultures were pulsed for 6 hours with BrdU. The cells were then fixed and
processed

for

BrdU,

SHP-1,

GFAP,

and

Neurofilament

immunohistochemistry.

Immunohistochemical procedures
Cultures were first rinsed twice for 5 minutes with 0.1 M Tris-HCl
buffer, pH 7.4. Cells which were labeled for CNP and 0X42 were fixed in
4% paraformaldehyde for 15 minutes, all others were fixed in ice-cold
methanol for 2 minutes. Cells were next rinsed in 0.1 M Tris-HCl buffer,
pH 7.4 and Tris-HCl buffer, pH 7.4 with 1% bovine serum albumin (BSA;
Sigma). Two additional steps were performed when labeling for BrdU; a 5
minute rinse in 0.0IM HCl followed by an additional Tris-HCl, pH 7.4
rinse. The cells were then incubated for 20 minutes in 4% normal horse
serum for monoclonal antibodies and 4% normal goat serum for polyclonal
antibodies.

All immunohistochemical reagents were prepared in 1%
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BSA/1 % sodium azide in Tris-HCl buffer, pH 7.4 [except for the avidin
biotin complex (ABC) reagent].

The cultures were incubated in the

primary antibody overnight; anti-BrdU (1:2000; Becton Dickinson); 205
(1:2000; a generous gift from Dr. Shen, Montreal Canada); anti-GFAP
(1:1500; DAKO); anti-Neurofilament (1:800; courtesy of Dr. Virginia Lee,
Philadelphia, PA.); anti-CNP (1:100; Promega); anti-OX42 (1:500; Serotec).
The next day, the cells were washed in Tris-HCl buffers, pH 7.4, incubated
in either biotinylated horse anti-mouse or biotinylated goat anti-rabbit
(monoclonal and polyclonal, respectively) at a concentration of 1:400. The
cells were then washed in Tris buffers, incubated in ABC (1:6 dilution;
Vectastain Elite ABC kit; Vector Labs) for 1 hour. The cells were rinsed for
10 minutes in Tris and developed with diaminobenzidine as the chromagen
(0.5 mg/ml; Sigma) with 0.1% H O and 1 mM imidazole in Tris-HCl buffer,
2

2

pH 7.4. For BrdU the diaminobenzidine was intensified with 0.08% nickel
chloride to create a black rather than a brown reaction product.

The

coverslips were then dehydrated and covers lipped using DPX (BDH
Laboratories).

Double-label immunohistochemistry
Cultures were rinsed twice for 5 minutes with O.IM Tris-HCl, pH 7.4
and then fixed. Cells were then rinsed three times for 5 minutes with
phosphate buffer saline (PBS), pH 7.4. Cells were blocked with either 4%
normal horse serum (NHS) or 4% normal goat serum for 20 minutes. This
and all other immunocytochemical reagents were prepared in 1% BSA in
PBS. The cells were next incubated in monoclonal antibodies (CNP-1:5
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0X42-1:10 and Neurofilament-1:10) or polyclonal antibodies (SHP-1-1:400,
GFAP-1:10) overnight at room temperature. The next day the cells were
rinsed three times for 5 minutes each with PBS, then incubated for 1 hour
in 1:200 biotinylated goat anti-rabbit linked to FTTC or Cy3 or 1:200
biotinylated horse anti-mouse linked to FTTC or Cy3 (Vector Labs). Cells
were then rinsed three times for 15 minutes in PBS, rinsed in ddH^O and
coverslipped with vectashield mounting media (Vector Labs).

Covalent Coupling of Fluorescein to Antibody
The polyclonal antibody ghal fibrillary acidic protein (GFAP) was
directly linked to fluorescein to allow for double labeling with two
polyclonal antibodies.
Haimovich (1983).
isothiocyanate

This protocol is modified from Schreiber and
Briefly, in the absence

(FTTC) was

dissolved

of light fluorescein

in absolute

ethanol,

at

a

concentration of 5 mg/ml. 250 |il IM sodium carbonate buffer (pH 9.0)
and the appropriate amount of FTTC (25 jig FITC/mg IgG) was added to
the GFAP antibody solution (Dako), vortexed and allowed to come to
ambient temperature. The FITC/antibody solution was passed over a G-50
Sephadex column. The FITC/antibody solution which passed through the
column was collected and the concentration of fluorescein-conjugated IgG
(mg/ml) and molar ratio of dye/protein was determined by absorbance at
280 nm and 493 nm.
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Immunohistochemical analysis
Quantification o f BrdU labeled cells
Cultures were viewed with a Nikon Eclipse E800 microscope at
magnifications ranging from 4-60X. BrdU positive cells within the cultures
were counted using NIH Image Analysis Program 1.61.
With a random start, nine random fields of 1.78 mm^ were analyzed
for each well. Slides were viewed with a microscope that was attached to
a COHU high performance CCD video camera connected to a Power
Macintosh 8600/200 computer. NIH Image 1.61 (image analysis software)
allowed the analysis of the digitized images. Once the image was digitally
captured the NIH Image 1.61 program macros were used to count the
number of BrdU positive cells. The total number of labeled cells were
calculated and averaged over the controls. Significant differences were
determined by a one-way ANOVA.

Quantification o f phosphatase immunoreactivity
The density of the phosphatase immunoreactivity within the
cultures was determined by using NIH Image Analysis Program 1.61. As
stated above, nine random fields were selected and the image captured on
the viewing screen. Once captured a density threshold was set for each
culture.

The mean density was measured and averaged over control

density. Significant differences were determined by a one-way ANOVA.

RESULTS

Neural/Glial Culture
Mixed neural/glial cultures were prepared from E14 chick
brainstems. Cultures contained both neural and glial cells as demonstrated
by immunocytochemical labeling for various cell types.

All cultures

contained a small number of neurons that were immunopositive for
neurofilament (Fig. 1A). Neurons were observed to be present at all times,
even through day 18 in culture. The neurons appeared to be viable and
healthy with intact cell bodies and many long processes. In some cases,
neurons appeared to be contacting each other (Fig. lA). In addition, the
cultures contained

astrocytes,

oligodendrocytes,

and

microgha as

demonstrated by immunostaining for GFAP, CNP, and 0X42 respectively
(Fig. IB, C, D). Finally, a subset of cells were inununopositive for SHP-1 in
vitro (Fig. IE). Staining was largely confined to the cytoplasm and the
initial segment of some glial processes. Thus, the in vitro system contains
neurons, all glial sub-types, and SHP-14- cells.

Identification of SHP-1 positive cells
A subset of all three glial cell types appear to express SHP-1 in
vitro. Control cultures (day 12) were double-labeled for SHP-1 and either
Neurofilament, GFAP, 0X42, and CNP. A few astrocytes, microglia, and
oligodendrocytes were found to be SHP-1+ (Fig. 2A, B, C). Neurons did
not appear to express SHP-1 (Fig. 2D). The presence of SHP-1 in aU three
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Fig. 1.

Mixed neural glial cultures contain

neurons, astrocytes,

oligodenrocytes, microglia, and SHP-1+ cells (Day-18 in culture).

A)

Neurons immunostained for neurofilament (RMO 270). Two large healthy
neurons (large arrows) with intertwined processes (small arrow). B) The
cultures contain many GFAP+ astrocytes (arrows). Bar=50)im (A and B).
C) CNP+ oligodendrocytes are found throughout the culture (arrows). D)
0X424- microglia are present in the culture (arrows). E) Many SHP-14cells are found in day 6 growing cultures.

Note the cytoplasmic

localization of the immunoreactivity (arrows). Bar=30|im (C, D, and E)
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Fig. 2. SHP-1 positive cells (red) at day 13 in culture. A) Few
differentiated GFAP+ astrocytes (green) are also SHP-1+ (arrows). B)
Many less differentiated GFAP+ (green) cells are SHP-1+ (arrows). C)
Several CNP+ oligodenrocytes (green) are SHP-1+ (arrow). D) Several
0X42+ microglia (green) are SHP-1+ (arrows). Bar=20)im E) No neurons
(green; arrow) appear to express SHP-1. Bar=80|iim
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glial cell types differs from previous findings in vivo, where only astrocytes
appear to become immunopositive for SHP-1 following deafferentation. In
the avian brainstem, astrocytes appear to be the only type of glial cell that
proliferates following deafferentation (Lurie and Rubel 1996; Lurie et al.
1998). In this system, the onset of astrocyte proliferation is correlated with
significant increases in SHP-1 immunoreactivity. However SHP-1+ cells do
not appear to enter the cell cycle. Therefore, it has been hypothesized that
the expression of SHP-1 plays a role in regulating the mitotic behavior of
these astrocytes (Lurie et al. 1998). Presumably all types of glial cells
proliferate in culture, and thus it is not unexpected that SHP-1 is expressed
by a sub-population of all three glial types.

Cellular proliferation.
In order to determine whether SHP-1 is playing a role in glial
proliferation, the expression of SHP-1 was examined when cultures were
either growing or growth arrested.

To establish the amount of glial

proliferation during the various growth conditions, 6 hour pulses of the
thymidine analogue 5’-Bromodeoxyuridine (BrdU) was introduced into
the cultures in order to label dividing cells. Visual inspection of BrdUlabeled cells at three times points, growing (Day-6), growth arrested (Day15) and serum addition/growing (Day-18), revealed that manipulation of
glial proliferation could be accomplished by serum deprivation (Fig. 3).
When cultures were growing towards confluence, there were many BrdU
positive cells (Day-6,growing; Fig. 3A). The number of proliferating cells
decreased after serum deprivation (Day-15, growth arrested; Fig. 3B) and
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Fig. 3. Brdu-positive cells during manipulation of the cell cycle. A) Note
the many BrdU+ cells at day 6 in culture (growing) (arrows). B) The
number of BrdU+ cells dramatically decreases after 6 days of serum
deprivation

(Day-15 in culture;

growth

arrested)

(arrows).

C)

Réintroduction of serum for 3 days (Day-18 in culture) results in increased
numbers of BrdU+ cells (arrows). Bar=50 pm
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Cellular Proliferation

CD

O)

200

G rowing
(D a y 6)

Figure 4:

Growth A rrested
(D a y 15)

S eru m Addition
(D a y 18)

Quantification o f proliferation o f cultures during different
grow ing conditions as described in methods. The Y -axis represents the
average number o f BrdU-labeled cells in nine random fields with each
culture. Serum depletion results in a significant decrease in proliferation.
Re-introduction o f serum results in a significant increase in proliferation
when compared to growth arrested cultures. Significant differences among
growing, growth arrested and serum addition cultures were determined
using a one-w ay A N O V A , * p < 0.0001.
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Fig. 5 SHP-1 immunoreactivity of cultures during manipulation of the cell
cycle. A) Growing cultures (Day-6) contain numerous SHP-1+ cells. Note
the cytoplasmic staining (arrows). B) Growth arrested cultures (Day-15)
contain areas devoid of any immunoreactivity.

C) Some areas of the

growth arrested cultures contain clusters (approximately 30%) of SHP-14cells with a nuclear distribution of immunoreactivity (arrows).

D) Re-

introduction of serum results in growing cultures (Day-18) with scattered
SHP-14- cells.

The immunoreactivity is once again localized to the

cytoplasm (arrows). Bar=30|im
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then increased again after serum was re-introduced into the cultures for
three days (Day-18, serum addition; Fig. 3C). The number of BrdU-labeled
cells was then quantified using image analysis techniques.

Serum

deprivation reduced the number of proliferating cells by 2.5 fold (Fig. 4);
however, we were unable to completely eliminate all cellular division by
serum depletion. The addition of serum back into the cultures increased
proliferation to within 73% of the original growing cultures (Fig. 4).
SHP-1 expression was then correlated to the different growth
conditions. At the earliest time point (Day-6), SHP-1 immunoreactivity was
distributed within the cytoplasm and initial segments of the processes in
some glial cells (Fig. 5A).

However, when the cultures were growth

arrested (Day-15), there was a distinct change in the pattern of SHP-1
immunoreactivity which fell into one of two distributions. Some areas of
the culture contained very little immunostaining for SHP-1 (Fig. 5B) while
in other areas the immunoreactivity for SHP-1 was localized to the nucleus
of clusters of cells (Fig. 5C). When cultures were induced to divide again
by re-introduction of serum, SHP-1 immunoreactivity once again appeared
to have a cytoplasmic distribution (Fig. 5D).

Addition of Sodium Orthovanadate
If SHP-1 plays a role in negatively regulating the glial cell cycle in
vitro, then inhibiting this phosphatase should result in increased glial
proliferation. In order to test this hypothesis, the nonselective tyrosine
phosphatase inhibitor sodium orthovanadate was added to growing
cultures at day 7 for 24 hr. Some cultures were then pulsed with BrdU for
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the last 6 hours of the 24 hr vanadate treatment and other cultures were
immunostained for SHP-1. Vanadate was found to be toxic to the cultures
at concentrations higher than 100 |iM, and caused the cells to lift off of the
coverslips and the cultures to become patchy (data not shown). However,
at concentrations below 100 |iM the cells appeared healthy.

Adding

vanadate to growing mixed neural/glial cultures resulted in a dose
dependent increase in cellular proliferation. Increases in cell division were
observed with the addition of as little as 10 |iM of vanadate to the cultures
and significant increases were observed with 20 |iM of vanadate (Fig. 6A,
C, E and Fig. 7). The highest dose of vanadate which did not produce cell
toxicity (50 jiM) resulted in an almost 3-fold increase in cellular
proliferation over controls (Fig. 7).
Interestingly, the expression of SHP-1 did not change significantly
with the addition of vanadate. While concentrations of 30 and 50 pM of
sodium orthovanadate appeared upon visual inspection to result in slightly
darker SHP-1 immunolabeling, quantification of the density of staining
throughout the cultures did not reveal significant increases over control
(Fig. 6B, D, F and Fig. 8).
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Fig. 6

Effects of sodium orthovanadate on proliferation and SHP-1

immunoreactivity. A and B- control cultures. C and D- 24 hr. of 30 jiM
vanadate. E and F- 24 hr. of 50 |Li M vanadate. (A, C, and E) Cultures are
labeled for BrdU-immunohistochemstry. Note the increase in the number
of BrduU-i- cells with increasing concentrations of vanadate. Bar=50 pm.
(B, D, and F) Immunostaining for SHP-1 does not appear to change
following the addition of vanadate. A similar number of cells continue to
display a cytoplasmic distribution of SHP-1 (arrows). Bar=30 pm
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24 hours after addition of sodium orthovanadate
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Figure 7:

The ratio o f the number o f BrdU+ cells after treatment o f sodium
orthovanadate over control. The Y-axis represents the ratio o f BrdU-labeled cells over
the control in nine random fields within each culture. There is a significant increase in
proliferation at concentrations o f vanadate > 20 fiM. Significant differences between
control and vanadate concentrations were determined using a one-way A N O V A , * p <

0 . 01 .
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SHP-1 Density Quantification
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Figure 8:

Quantification o f density o f immunoreactivity o f SHP-1 after the
addition o f vanadate to the cultures. The Y -axis represents the ratio o f
density o f SHP-1 immunoreactivity over the control cultures. There was no
significance difference among the control, 30 |iM , and 50 p.M vanadate
groups, determined using a one-w ay A N O V A .
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Addition of Growth Factors
Growth factors are thought to play a key role in regulating the glial
response to injury. We therefore investigated whether a variety of growth
factors influenced SHP-1 expression in vitro. We chose to examine three
growth factors that have been shown to interact with either the SHP-1
protein itself and/or lead to increased glial proliferation in other CNS
culture systems.

EOF addition
Epidermal growth factor (EOF) has been demonstrated to be
mitogenic for a variety of astrocytes in vitro (Langan et al. 1994; Huff and
Scheier 1990). Our cultures also responded to EOF with an increase in
cellular proliferation. To establish the amount of glial proliferation induced
by the addition of EOF, BrdU was introduced into the cultures during the
last 6 hours of either 24 or 72 hr. of EOF treatment in order to label
dividing cells. Parallel control cultures received serum rather than EOF and
were also pulsed with BrdU. The number of BrdU-labeled cells within nine
random fields per culture were then counted.
EOF significantly increased proliferation at all concentrations (20320 ng/ml) when compared to growth arrested cultures at 24 hr. (Fig. 9).
In addition, there was a significant increase in proliferation (> 20%) over
the serum controls for concentrations > 40 ng/ml (Fig. 9).
The expression of SHP-1 after the addition of EOF differs from that
of the serum controls. Unlike the cytoplasmic distribution of SHP-1 in
serum cultures (Fig, lOB), the distribution of SHP-1 after the addition of
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Figure 9: The ratio o f the number o f BrdU+ cells after EGF treatment for 24
hr. over control cultures. The Y -axis represents the ratio o f BrdU-labeled cells
over controls in nine random fields within each culture. The significance was
determined using a one-w ay A N O V A , p < 0.0001-0.05. EGF significantly
increased proliferation at all concentrations (20-320 ng/ml) when compared to
growth arrested cultures. In addition, there was a significant increase in
proliferation ( > 20%) over the serum controls for concentrations_> 40 ng/ml.
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Fig. 10. SHP-1 immunoreactivity 24 hr. following the addition of growth
factors. A) SHP-1 immunostaining in growth arrested cultures (Day-16).
SHP-1 immunoreactivity is localized to the nucleus (arrows).

B) SHP-1

immunostaining in cultures after the réintroduction of serum (Day-16).
Note the cytoplasmic distribution of SHP-1 staining (arrows). C and DSHP-1 immunostaining after the addition of EGF (Day-16). C) Many cells
display a dark area of staining located just below the nucleus (arrows). D)
Other cells exhibit a nuclear distribution of immunoreactivity (arrows). E)
SHP-1 immunostaining after the addition of GM-CSF (Day-16).

Many

large, vacuolated cells are darkly stained for SHP-1 (arrows). Some cells
have both cytoplasmic and nuclear staining (arrow).

F)

SHP-1

immunostaining after the addition of IL-3 (Day-16). Note the many large,
vacuolated inununopositive cells (arrows) that resemble those seen
following GM-CSF treatment. Bar=30 jim
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EGF appears to be largely nuclear (Fig. IOC, D). This is a similar staining
pattern to that of the growth arrested cultures (Fig. 10A) with strong
inununopositive staining in or around the nucleus. Small, dense areas of
immunostaining located just below the nuclear membrane can also be seen
in approximately 80% the EGF treated cultures (Fig. IOC).

GM-CSF addition
GM-CSF treatment has been shown to regulate mitogenic signaling
in mouse macrophages as well as potentially dephosphorylating novel
substrates critical for GM-CSF signaling (Yang et al. 1998), making it a
potential candidate for influencing SHP-1 expression following injury.
GM-CSF was therefore introduced to growth arrested cultures on day 15
for 24 hours and the cultures were then pulsed with BrdU as described
above. GM-CSF increased cellular proliferation by at least two-fold over
serum depleted cultures at all concentrations (10-640 ng/ml; Fig. 11). GMCSF also induced a 36% increase in proliferation over serum addition at
concentrations > 40 ng/ml (Fig. 11).
Addition of GM-CSF results in a subset of cells that display dark
cytoplasmic as well as nuclear staining (Fig. lOE). This contrasts with the
expression pattern seen in growth arrested or serum treated cultures, which
contain a nuclear or cytoplasmic distribution, respectively (Fig. 10A, B). In
addition, many of the SHP-1+ cells appear to have vacuolated staining in
the cytoplasm, which may reflect immunostaining around mitochondrial
membranes (Fig. lOE).
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24 hours after addition of GM-CSF
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Figure 11: The ratio of the number of BrdU+ cells after GM-CSF
treatment for 24 hr. over control cultures. The Y-axis represents the ratio
of BrdU-labeled cells over controls in nine random fields within each
culture. The significance was determined using a one-way ANOVA, p <
0.0001-0.05. GM-CSF significantly increased proliferation at all
concentrations (10-640 ng/ml) when compared to growth arrested
cultures. In addition, there was a significant increase in proliferation ( >
36%) over the serum controls for concentrations _> 40 ng/ml.
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IL-3 addition

SHP-1 has been found to bind to, and dephosphoryiate interleukin3 (IL-3) in myeloid cells. However, its effects on avian neural and glial
cells are not known. Therefore, IL-3 was the third type of growth factor
introduced into growth arrested cultures. Addition of IL-3 resulted in a
1.8-fold increase in proliferation at all concentrations (2-44 ng/ml) over
growth arrested cultures. Interestingly, unlike EGF and GM-CSF, IL-3 did
not cause a significant increase in proliferation over serum addition (Fig.
12).

The pattern of SHP-1 immunoreactivity following the addition of IL3 is similar to that induced by GM-CSF. Some cells contained very darkly
labeled cytoplasm and nucleus and some areas of the cultures contained
cells with nuclear staining only (Fig. lOF). In addition, the vacuolated
pattern of immunostaining seen with GM-CSF as also seen with IL-3 (Fig.
lOF).
Finally, no additional increase in cellular proliferation was observed
when growth factors were added to cultures for 72 rather 24 hours (data
not shown). In fact, BrdU incorporation decreased slightly at 72 hours,
presumably because the cultures were confluent by this time. Likewise,
cultures which had been treated for 24 and 72 hours did not differ in SHP1 expression or distribution.
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24 hours after addition of IL-3
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Figure 12: The ratio of the number of BrdU+ cells after IL-3 treatment
for 24 hr. over control cultures. The Y-axis represents the ratio of BrdUlabeled cells over controls in nine random fields within each culture. The
significance was determined using a one-way ANOVA, p < 0.0001. IL-3
significantly increased proliferation at all concentrations (2-44 ng/ml)
when compared to growth arrested cultures.
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NMDA
Injury to the CNS in vivo often results in degeneration of neural
cell bodies and their processes. It may be that neuronal debris plays a role
in signaling the upregulation of SHP-1 expression in the brain following
damage. In order to investigate this possibility, NMDA was added to
confluent cultures presumably to excitotoxically kill neurons but leave
glial cells intact. Both control cultures and NMDA-treated cultures were
then examined for the distribution of SHP-1+ and GFAP+ glia within the
entire culture as well as relative to intact and damaged neurons.
In control cultures, SHP-1+ and GFAP+ cells were found distributed
throughout the culture as well as underneath or directly adjacent to the
neurons (Figs. 13A, 14A). The addition of NMDA to cells at day 11 in
culture resulted in neuronal degeneration at concentrations of 75-lOOpM
after 48hrs. At these toxic concentrations, SHP-1+ cells were now found
to be located some distance away from dying neurons and neuronal debris
(Fig. 13B). While clusters of SHP-1+ cells could be observed in areas of
the culture that did not contain neurons (data not shown), cells
underneath and/or directly adjacent to dying neurons and neuronal
fragments

were

SHP-1

negative

(Fig.

13B).

In

contrast,

GFAP

immunoreactivity increased both beneath and surrounding dying neurons
and neuronal debris (Fig. 14B). In addition, there appears to be an overall
increase in GFAP+ astrocytes throughout the cultures 48hrs following the
addition of toxic concentrations of NMDA.
It is important to note that this increase in GFAP immunoreactivity
does not appear to be correlated with an increase in glial proliferation. The
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addition of NMD A (25-100 |xM) did not result in a significant increase in
proliferation at either 24 (Fig. 15) or 48 hours (Fig. 16).
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Fig. 13 Mixed neural/glial culture immunostained for neurofilament and
SHP-1. A) Control culture (Day-13). The SHP-1+ cells (arrows) surround
the neuron and it’s processes (shown in green). B) Following 48 hr. of
100 ixM NMDA, there is a decrease in SHP-1 + cells (arrows) around the
dying neuron. Bar=80|im
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Fig. 14. Mixed neural/glial culture immunostained for neurofilament and
GFAP. A) Control culture (Day-13). The GFAP+ cells (arrows) surround
the neuron and it’s processes (shown in green). B) Following 48 hr. of
100 \\M NMDA, there is a dramatic increase in GFAP+ cells (arrows)
around and beneath the dying neuron. Bar=80|im
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Figure 15: The ratio of the number of BrdU+ cells after NMDA treatment for 24
hr. over control cultures. The Y-axis represents the ratio of BrdU-labeled cells
over controls in nine random fields within each culture. NMDA did not
significantly increase proliferation at any concentrations (25-100 pM).
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48 hours after addition of NMDA
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Figure 16; The ratio of the number of BrdU+ cells after NMDA treatment for 48 hr.
over control cultures. The Y-axis represents the ratio of BrdU-labeled cells over
controls in nine random fields within each culture. NMDA did not significantly
increase proliferation at any concentrations (25-100 pM).

D IS C U SSIO N
A subset of astrocytes, oligodendrocytes, and microglia within
mixed neural/glial cultures

of the

chiçk

auditory

brainstem

are

immunopositive for SHP-1. Neurons do not appear to express SHP-1. This
distribution differs from previous in vivo findings where deafferentation of
the

avian

auditory

brainstem results

in an

increase

in

SHP-1

immunoreactivity within astrocytes only (Lurie et al. 1998). In this injury
model, the onset of increased SHP-1 immunoreactivity is correlated
temporally with an increase in astrocyte proliferation, and astrocytes are
the only class of glia that proliferate following deafferentation in the
chicken auditory brainstem. SHP-1 + astrocytes do not appear to be those
which enter the cell cycle and it has been hypothesized that the
expression of SHP-1 plays a role in negatively regulating the mitotic
behavior of astrocytes following deafferentation or other injury (Lurie et
al. 1998) perhaps in order to prevent a pathological formation of large glial
masses at the lesion site. The hypothesis that SHP-1 expression may
negatively

regulate

astrocyte

proliferation is in

agreement

with

observations in other systems where SHP-1 activity has been found to be
inversely related to growth and proliferation of cells (Lopez et al. 1996;
1997; Cambillau et al. 1995;Uchida et al. 1993; Zhao et al. 1994; Yi et al.
1993).
Our present finding that SHP-1 is present in microglia and
oligodendrocytes as well as astrocytes in vitro, may reflect the fact that aU
three glial subtypes would be expected to proliferate in culture. If SHP-1 is
expressed in those populations of cells that are dividing in order to
regulate the extent of cell division, then it is not unexpected that a subset
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of all glial cells are immunopositive for SHP-1 while neurons do not label
for the enzyme. However, we have not yet been able to directly show that
SHP-1 + cells are not BrdU positive. Studies are currently underway using
other cell cycle markers such as cyclin antibodies to confirm that SHP-1+
glial cells do not proliferate. Interestingly, to date, astrocytes have been
the only glial cell type that have been described to contain SHP-1. The
present study is the first report of SHP-1 expression in microglia and
oligodendrocytes (Lurie et al. 1998; Massa and Wu. 1996).

Manipulation of the cell cycle
Manipulating the cell cycle of the mixed neural/glial cultures alters
both the number of immunoreactive cells and the distribution of SHP-1
staining. Specifically, growth arrest of the cultures results in large areas
that contain no SHP-1 immunoreactivity. However, there are clusters of
SHP-l-k cells that are widely scattered throughout the culture.

These

immunopositive cells show a nuclear rather than a cytoplasmic distribution
of SHP-1 staining, indicating that the enzyme has translocated to the
nucleus following growth arrest. This observation is in agreement with
published reports in other systems, where the redistribution of SHP-1 in
response to signaling has been noted.

For example, the phorbol ester,

phorbol 12-myristate 13-acetate (PMA) has been shown to induce SHP-1
expression as well as produce a translocation of SHP-1 from the cytoplasm
to a plasma membrane (Zhao et al. 1994). In addition, growth hormone has
been shown to both increase SHP-1 activity and induce a translocation of
most of the enzyme from the cytoplasm to the nucleus in rat liver cells
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(Ram and Waxman 1997). Finally, localization of SHP-1 may reflect its
activity. When the enzyme is localized to the cytosol of HL-60 cells, its
activity is at a minimum, but when a lipoprotein such as PMA is added, the
enzyme translocates to a lipid membrane and its activity is increased 10^ to
10"^ fold (Zhao et al. 1994). It may be that the translocation we observe
during growth arrest reflects the activity of SHP-1. Our laboratory is in the
process of developing a SHP-1-specific activity assay that should yield
insight into the enzymatic activity of SHP-1 during localization to the
cytoplasm vs. the nucleus.
One factor that should be considered in these studies is the fact that
we were unable to completely growth arrest the cultures.

Serum

deprivation for 6 days was found to significantly growth arrest the
cultures, but not completely eliminate all cell division. We attempted to
extend the time in the serum free-medium (B-27) but were never able to
completely stop all cell division. In addition, when the time in serum-free
medium was extended, the cultures became slightly more confluent, thus
decreasing the amount of inducible proliferation after serum was re
introduced.

We also found that the amount of proliferation after re-

introduction of serum was slightly less than the proliferation observed
during the initial growth stage. This was presumably due to the fact that
the cultures were slightly more confluent following the 6 days of semm
deprivation and contact inhibition may a played a role in reducing the
amount of glial proliferation.

Ara-C was also used in our initial

experiments in an attempt to completely stop all cell division. However,
concentrations of Ara-C that were not toxic to the cells did not
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successfully stop all proliferation, while higher concentrations resulted in
cellular degeneration.
It is clear, though, that the expression of SHP-1 immunoreactivity
changes during the three different growth conditions: serum (initial
growth), serum-deprivation (growth arrested), and réintroduction of serum
(growing). The observation that the immunoreactivity of SHP-1 changes
when the cultures are actively dividing versus growth arrested, supports
the hypothesis that SHP-1 may be involved in those cellular cascades that
regulate the cell cycle. Its role is likely to be very complex in light of the
fact that SHP-1 immunostaining is not eliminated during growth arrest and
areas of the culture contain groups of cells that are SHP-1+. These clusters
of SHP-I+ cells do not appear to be correlated with areas of dividing cells,
those few remaining BrdU+ cells are widely scattered throughout the
growth arrested cultures and are not localized to any particular region.
The finding that the SHP-1 enzyme appears to be located in different
cellular compartments (i.e. cytoplasmic vs. nuclear) when cells are
proliferating versus when they are quiescent is intriguing, and may reflect
functional properties of this enzyme.

Sodium orthovanadate
The hypothesis that SHP-1 plays a role in negatively regulating the
glial cell cycle was tested by the addition of sodium orthovanadate.
Vanadate is a general FTP inhibitor (Swamp et al. 1982) whose
mechanisms of actions have not been investigated in detail, but have been
shown

to inhibit SH2 domain containing

tyrosine

phosphatases
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(Pugazhenthi et al. 1996; Huyer et al. 1996). Vanadate is a phosphate
analog and is generally thought to bind as a transition state analog to the
phosphoryl transfer enzymes that it inhibits, since it can easily adopt a
trigonal-bipyramidal structure (Goldfine et al. 1995). Vanadate has a wide
array of effects on biological systems (Shechter 1990). It is an insulinmimetic and has been shown in human clinical trials to be potentially
useful in treating both insulin- and non-insulin-dependent diabetes and it
has been suggested that part of vanadate’s insuhn-mimetic effect may be
due to its inhibition of FTPs (Shechter 1990). However, vanadate is a non
specific tyrosine phosphatase inhibitor and will thus inhibit the activity of
SHP-1 as well as other tyrosine phosphatases.
The addition of vanadate into growing cultures resulted in an
increase in cellular proliferation over serum control.

Thus, inhibition of

phosphatase activity did increase the number of BrdU labeled cells,
indicating a strong correlation between tyrosine phosphatase activity and
inhibition of cellular proliferation. Vanadate has also been shown to alter
the regulation of IFN-gamma-signaling in mouse astrocytes in similar ways
to astrocytes that do not contain SHP-1 (Massa and Wu 1996), implicating
a role for SHP-1 in this signaling cascade.

However, it is clear that a

specific inhibitor for SHP-1 will have to be developed in order to
definitively show that SHP-1 is a key player in these systems and is the
phosphatase that negatively regulates glial proliferation in the avian
brainstem.
The addition of vanadate did not appear to significantly alter SHP-1
expression and/or distribution within the cultures. Quantification of the
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amount of immunostaining throughout the entire culture did not reveal
any significant differences at any of the concentrations of vanadate.
Specifically, vanadate neither increased nor decreased the total amount of
SHP-1 expressed within the culture.

Visual inspection revealed that

perhaps a slight increase in the density of SHP-1 staining within some
individual glial cells occurred with the addition of vanadate, but this did
not seem to be the case for every SHP-1 + cell.

Finally, SHP-1

immunoreactivity remained localized to the cytoplasm following vanadate
treatment and did not appear to translocate to the nucleus.

Thus,

inhibition of tyrosine phosphatase activity does not seem to alter either the
amount, or localization, of SHP-1 immunoreactivity within our culture
system.

Growth factors
Both the signals that activate SHP-1 in vivo, as well as its substrates,
are as yet unknown and the signal transduction pathway of SHP-1 has not
been fully elucidated.

However, SHP-1 is involved in growth factor

mediated signal transduction in a variety of different cells. For example,
SHP-1 binds to the interleukin 3 (IL-3) receptor following ligand binding
(Yi and Ihle 1993) and also associates with, and can dephosphorylate,
activated EOF receptors (You and Zhao 1997; Tenev et al. 1997; Tomic et
al. 1995). In addition, SHP-1 has been shown to play an important role in
downregulating GM-CSF mitogenic signaling in motheaten macrophages
(Yang et al. 1997). Our finding that the addition of these three growth
factors (EOF, IL-3, and GM-CSF) to our serum depleted cultures resulted in
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increased cellular proliferation confirms that these growth factors are
mitogenic for avian CNS cells. All three of these factors have been shown
to be mitogenic for astrocytes in vitro in other systems (Langan et al.
1994; Huff and Scheier 1990; Malhotra et al. 1990) and have also been
demonstrated to interact with SHP-1.
Growth factors and their receptors are excellent candidate signaling
molecules for SHP-1 and other tyrosine phosphatases due to the fact that
growth factor receptors of the tyrosine kinase-type undergo rapid
autophosphorylation upon ligand stimulation (Schlessinger and Ullrich
1992; Fantl et al. 1993). This autophosphorylation generates binding sites
for SH2 domain containing intracellular proteins. Membrane recruitment
of these molecules by binding to the autophosphorylated growth factor
receptors is considered an important step in the activation of several
intracellular signaling cascades which ultimately lead to cellular responses
such as cellular division, differentiation, or locomotion (Schlessinger and
Ullrich 1992).

Dephosphorylation of the autophosphorylated growth

factor receptors by PTPases presents a major mechanism of negative
regulation of tyrosine kinase receptor signaling. SHP-1 has been shown to
interact with multiple growth factors and their receptors and to modulate
their activity (Schlessinger and Ullrich 1992; Feng and Pawson 1994),
which could presumably lead to alterations in cell division and
differentiation.
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EGF
SHP-1 has been shown to associate with and dephosphorylate
epidermal growth factor receptors (Tomic et al. 1995; Tenev et al. 1997;
You and Zhao. 1997). Inactivation of SHP-1 by a point mutation of the Cterminus SH2-domain slightly reduces its association with the EGF
receptor, but a point mutation at the N-terminus SH2-domain leads to a
large reduction in association, indicating that the SH2-domain responsible
for binding of SHP-1 to the EGF receptor is the N-terminus SH2 domain
(Tenev et al. 1997). Thus, the catalytic domains of SHP-1 are thought to
provide specificity for the interaction with the EGF receptor although
functional interactions of SHP-1 with the EGF receptor requires
association that is mediated by both SH2 domains (Tenev et al. 1997).
The addition of EGF for 24 hours to our serum deprived cultures led
to at least a two-fold increase in BrdU-incorporation at all concentrations
examined. EGF also induced significantly more proliferation than serum at
concentrations of 40 ng/ml and higher. This result was not unexpected
given that EGF has been shown to be mitogenic for astrocytes in other in
vitro systems (Langan et al. 1994; Huff and Scheier 1990; Malhotra et al.
1990). In addition to increased proliferation, EGF resulted in a nuclear
distribution of SHP-1 in those cells that were immunoreactive. This dark
nuclear immunostaining of SHP-1 resembled the nuclear staining of SHP-1
when the cultures were growth arrested.

Dark areas of perinuclear

immunoreactivity could also be seen following EGF treatment.

The

relationship between this pattern of SHP-1 immunoreactivity and its
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activity following EGF stimulation remains to be elucidated. Intriguingly,
SHP-1 is thought to play a positive role in EGF-activated mitogenesis in
human embryonic kidney cells (Su et al, 1996). Whether SHP-1 plays a
positive or negative role in EGF-activated mitogenesis in avian CNS
cultures will require further studies.

GM-CSF
SHP-1 has been shown to be involved in downregulating GM-CSF
mitogenic

signaling

in

motheaten

macrophages

and

may

also

dephosphorylate novel substrates critical for GM-CSF signaling in these
macrophages (Yang et al. 1997). GM-CSF has also been shown to be
secreted by astrocytes and can stimulate the in vitro proliferation of simian
astrocytes (Guillemin et al. 1996), as well as induce IL-6 production by
mouse microglia (Suzumura et al. 1996). Finally, GM-CSF has also been
demonstrated to result in microglial proliferation and can also facilitate the
ramification of rat microglia in vitro (Fujita et al. 1996; Lee et al. 1994).
The addition of GM-CSF to our cultures caused an increase in
proliferation similar to that seen with the addition of EGF, indicating that
GM-CSF is mitogenic for avian CNS cells. GM-CSF also induced a 36%
increase in proliferation over serum addition at concentrations > 40 ng/ml.
However, the immunostaining for SHP-1 differed from that seen with EGF
in that GM-CSF induced a cytoplasmic as well as a nuclear distribution.
The cytoplasmic staining often appeared vacuolated, which may reflect
immunoreactivity around mitochondrial membranes. It is interesting that
both EGF and GM-CSF result in a similar increase in proliferation but have

59

very different patterns of SHP-1 immunoreactivity. It may be that GM-CSF
and EGF act on different types of cells within our mixed neural/glial
cultures or that the differential staining pattern reflects different functional
states of SHP-1.

IL-3
IL-3 has been detected in hippocampal and septal murine neurons
(Konishi et al, 1994) as well as rat microglial cells (Gebicke-Haerter et al.
1994; Ganter et al. 1992). Microglia have also been found to express
mRNA for IL-3 receptors (Sawada et al. 1993). SHP-1 has been shown to
associate with the IL-3 receptor and may also regulate mitogenic signaling
by IL-3 (Yang et al. 1998; Yi et al. 1993; Bone et al. 1997). IL-3 is a potent
mitogen for microglia both in vivo and in culture (Gebicke-Haerter et al.
1994; Ganter et al. 1992) and SHP-1 may play a role in this signaling
cascade. SHP-1 has been shown to bind to IL-3 in the cytosol of the cells
after it has been internalized and may regulate IL-3 mediated signal
transduction pathways (Bone et al. 1997).
The addition of IL-3 to our growth arrested cultures resulted in an
increase in proliferation similar to that seen with EGF and GM-CSF.
However, no concentration of IL-3 tested produced a significant increase
in proliferation over the addition of serum.

The pattern of SHP-1

immunoreactivity following the addition of IL-3 was similar to that
induced by GM-CSF rather than serum or EGF.
This similarity in SHP-1 immunoreactivity between GM-CSF and IL3 may reflect similarities in 1) the structure of GM-CSF and IL-3 receptors

60

and 2) the mediation of mitogenic signal transduction. The receptors for
GM-CSF and IL-3 share a common beta chain and both growth factors, as
well as EGF use tyrosine phosphorylation to control proliferation (MireSluis et al. 1995). Of particular interest is the finding that GM-CSF and IL3-induced proliferation is stimulated by a tyrosine phosphatase inhibitor in
a human erythroleukemia cell line while IL-5 induced proliferation is
inhibited (Mire-Sluis et al. 1995).

Both growth factors also induce

microglial proliferation. The large, darkly stained and vacuolated SHP-1+
cells that are present in our cultures following GM-CSF and IL-3 treatment
resemble the OX42-labeled microglia. In contrast, the SHP-1+ cells that are
present following EGF treatment appear to be much smaller cells and more
closely resemble astrocytes. It may be that EGF induces SHP-1 expression
primarily in astrocytes while GM-CSF and IL-3 induce SHP-1 expression in
microglia. Further studies are needed to confirm this hypothesis. It would
also be of interest to determine whether EGF results in astrocyte
proliferation while GM-CSF and IL-3 results in microglial proliferation.

NMDA
Following deafferentation of the chick auditory brainstem, SHP-1
immunoreactivity increases to a peak three days following cochlea removal
(Lurie et al. 1998).

At this time, there is a 30% neuronal loss with

accompanying axonal degeneration in the primary auditory nucleus.

It

may be that this neuronal cell death plays a role in the upregulation of
SHP-1 immunoreactivity in vivo.
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Therefore, NMDA was added to the avian brainstem cultures in
order to kill neurons and leave the glial cells intact. NMDA is a known
selective glutamate receptor agonist and is found on neuronal post
synaptic terminals. Application of NMDA results in excitotoxic neuronal
death due to excessive activation of NMDA receptors. To date no known
NMDA receptors have been found on glial cells and therefore NMDA is
thought to induce excitotoxicity in neurons only.

Over-activation of

NMDA receptors leads to an increase of Ca^^ into the cell (Ferreira et al.
1996), which in turn activates several cascades ultimately leading to
neuronal death. These cascades include activation of phospholipases and
proteases, cellular breakdown, and DNA fragmentation (Lynch and
Dawson 1994).
Application of NMDA to our cultures resulted in neuronal
degeneration but did not appear to induce any increases in cellular
proliferation. However, due to technical considerations, we have not yet
been able to double-label cultures for both BrdU and neurofilament in
order to

determine

whether

glial proliferation

increased

around

degenerating neurons. Careful examination of BrdU-labeled cultures that
have been treated with neurotoxic concentrations of NMDA reveals a
fairly uniform distribution of proliferative cells rather than clusters of
BrdU+ cells.
In contrast to undamaged neurons, most degenerating neurons are
located in areas that are devoid of SHP-1 immunostaining. In untreated
cultures, SHP-1+ cells are found throughout the culture, and many neurons
are surrounded by SHP-1 immunoreactivity. Following NMDA treatment,

62

clusters of SHP-1+ cells are located at a distance from the dead or dying
neurons, but few SHP-1 + cells remain directly adjacent to the neuronal
fragments. This differs from the pattern of GFAP immunoreactivity, where
many GFAP+ astrocytes are located around and beneath the dying
neurons. These results are particularly intriguing given the fact that our in
vivo findings indicate that at least initially following deafferentation, SHP1+ astrocytes represent a different population of cells than the GFAP+
astrocytes (Lurie et al. 1998).

It may be that neuronal degeneration

induces the activation of GFAP+ astrocytes while other factors are
involved in signaling an increase in SHP-1 + glia.

Conclusions
Based upon the information presented for this thesis, several
conclusions can be drawn:

1.

Manipulation of the cell cycle in chick brainstem cultures was

successfully accomplished and this manipulation changed the distribution
of SHP-1 immunoreactivity..

2.

The cell types that contain SHP-1 are of glial origin demonstrating

that SHP-1 is expressed in those cells which are able to proliferate after
injury in vitro.

63

3.

Introduction of the protein tyrosine phosphatase inhibitor, sodium

orthovanadate, increased the proliferation of the cultures indicating a
relationship between

phosphatase

activity and the

regulation

of

proliferation.

4.

Addition of specific growth factors (IL-3, EGF and GM-CSF)

resulted in different expression patterns of SHP-1. It may be that SHP-1 is
involved in more than one signal transduction cascade regulating cellular
division.

5.

Neuronal degeneration results in little SHP-1 immunoreactivity in

the immediate vicinity of dead and dying neurons.

This contrasts with

GFAP+ astrocytes, which are located around and beneath areas of neural
degeneration.
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